Sarah Foster 4/13/26 Sarah Foster 4/13/26 Travere Therapeutics Receives Full FDA Approval of FILSPARI, the First Approved Medicine for FSGS Read More Sarah Foster 2/26/26 Sarah Foster 2/26/26 Neurogene Receives FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome Read More Sarah Foster 2/10/26 Sarah Foster 2/10/26 Evommune's EVO301 Delivers Positive Top-Line Phase 2a Results in Atopic Dermatitis Read More Sarah Foster 2/4/26 Sarah Foster 2/4/26 Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial of DPTX3186 Read More Kimberly Hicks 8/13/25 Kimberly Hicks 8/13/25 argenx Delivers Strong First Half Performance! Read More Kimberly Hicks 8/11/25 Kimberly Hicks 8/11/25 Alnylam Pharmaceuticals continues to lead in RNAi therapeutics with a standout quarter! Read More Kimberly Hicks 8/5/25 Kimberly Hicks 8/5/25 Apellis Pharmaceuticals receives FDA approval of EMPAVELI® (pegcetacoplan) Read More Kimberly Hicks 5/20/25 Kimberly Hicks 5/20/25 argenx Kicks Off 2025 with Record-Breaking Growth Read More Kimberly Hicks 5/10/25 Kimberly Hicks 5/10/25 Big Moves in AI-Driven Oncology: Pathos Secures Major Backing Read More Kimberly Hicks 5/9/25 Kimberly Hicks 5/9/25 Another strong quarter for our client Alnylam Pharmaceuticals Read More Kimberly Hicks 3/24/25 Kimberly Hicks 3/24/25 Pathos has officially dosed the first patient in its Phase 1b/2a clinical trial evaluating Pocenbrodib. Read More Kimberly Hicks 3/21/25 Kimberly Hicks 3/21/25 Congratulations to Alnylam Pharmaceuticals on the FDA Approval of Amvuttra. Read More Kimberly Hicks 2/19/25 Kimberly Hicks 2/19/25 Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate! Read More Newer Posts
Sarah Foster 4/13/26 Sarah Foster 4/13/26 Travere Therapeutics Receives Full FDA Approval of FILSPARI, the First Approved Medicine for FSGS Read More
Sarah Foster 2/26/26 Sarah Foster 2/26/26 Neurogene Receives FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome Read More
Sarah Foster 2/10/26 Sarah Foster 2/10/26 Evommune's EVO301 Delivers Positive Top-Line Phase 2a Results in Atopic Dermatitis Read More
Sarah Foster 2/4/26 Sarah Foster 2/4/26 Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial of DPTX3186 Read More
Kimberly Hicks 8/13/25 Kimberly Hicks 8/13/25 argenx Delivers Strong First Half Performance! Read More
Kimberly Hicks 8/11/25 Kimberly Hicks 8/11/25 Alnylam Pharmaceuticals continues to lead in RNAi therapeutics with a standout quarter! Read More
Kimberly Hicks 8/5/25 Kimberly Hicks 8/5/25 Apellis Pharmaceuticals receives FDA approval of EMPAVELI® (pegcetacoplan) Read More
Kimberly Hicks 5/20/25 Kimberly Hicks 5/20/25 argenx Kicks Off 2025 with Record-Breaking Growth Read More
Kimberly Hicks 5/10/25 Kimberly Hicks 5/10/25 Big Moves in AI-Driven Oncology: Pathos Secures Major Backing Read More
Kimberly Hicks 5/9/25 Kimberly Hicks 5/9/25 Another strong quarter for our client Alnylam Pharmaceuticals Read More
Kimberly Hicks 3/24/25 Kimberly Hicks 3/24/25 Pathos has officially dosed the first patient in its Phase 1b/2a clinical trial evaluating Pocenbrodib. Read More
Kimberly Hicks 3/21/25 Kimberly Hicks 3/21/25 Congratulations to Alnylam Pharmaceuticals on the FDA Approval of Amvuttra. Read More
Kimberly Hicks 2/19/25 Kimberly Hicks 2/19/25 Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate! Read More
